Azole preexposure affects the Aspergillus fumigatus population in patients

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 9, 2012, Pages 4948-4950

  Alanio, Alexandre ^a,b   Cabaret, Odile ^b   Sitterlé, Emilie ^b   Costa, Jean Marc ^b   Brisse, Sylvain ^a   Cordonnier, Catherine ^b   Bretagne, Stéphane ^a,b  

^a INSTITUT PASTEUR   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 51A; ITRACONAZOLE; POSACONAZOLE; PYRROLE; STEROL 14ALPHA DEMETHYLASE; UNCLASSIFIED DRUG; VORICONAZOLE;

ARTICLE; ASPERGILLUS FUMIGATUS; DRUG EXPOSURE; FUNGUS ISOLATION; GENE CLUSTER; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INVASIVE ASPERGILLOSIS; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; POPULATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, FUNGAL; FUNGAL PROTEINS; GENOTYPE; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; MULTIGENE FAMILY; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIMIDINES; TRIAZOLES;

EID: 84865422021     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05990-11     Document Type: Article

References (30)

1. Alanio A, Cordonnier C, Bretagne S. 2011. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies - authors' response. J. Antimicrob. Chemother. 66:955. doi:10.1093/jac/dkr022.
2. Alanio A, Cordonnier C, Bretagne S. 2011. Azole resistance in Aspergillus fumigatus - current epidemiology and future perspectives. Curr. Fungal Infect. Rep. 5:168-178.
3. Alanio A, et al. 2011. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J. Antimicrob. Chemother. 66:371-374.
4. Alvarez-Perez S, Garcia ME, Bouza E, Pelaez T, Blanco JL. 2009. Characterization of multiple isolates of Aspergillus fumigatus from patients: genotype, mating type and invasiveness. Med. Mycol. 47:601-608.
5. Arendrup MC, et al. 2010. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One 5:e10080. doi:10.1371/journal.pone.0010080.
6. Bart-Delabesse E, Cordonnier C, Bretagne S. 1999. Usefulness of genotyping with microsatellite markers to investigate hospital-acquired invasive aspergillosis. J. Hosp. Infect. 42:321-327. (Pubitemid 29401520)
7. Bart-Delabesse E, Humbert JF, Delabesse E, Bretagne S. 1998. Microsatellite markers for typing Aspergillus fumigatus isolates. J. Clin. Microbiol. 36:2413-2418. (Pubitemid 28380928)
8. Brisse S, et al. 2009. Uneven distribution of mating types among genotypes of Candida glabrata isolates from clinical samples. Eukaryot. Cell 8:287-295.
9. Bueid A, et al. 2010. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J. Antimicrob. Chemother. 65:2116-2118.
10. Chowdhary A, et al. 2012. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J. Antimicrob. Chemother. 67:362-366.
11. Cornely OA, et al. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359. (Pubitemid 46148777)
12. de Valk HA, Meis JFGM, Klaassen CHW. 2007. Microsatellite based typing of Aspergillus fumigatus: strengths, pitfalls and solutions. J. Microbiol. Methods 69:268-272. (Pubitemid 46551296)
13. Enache-Angoulvant A, et al. 2010. Multilocus microsatellite markers for molecular typing of Candida glabrata: application to analysis of genetic relationships between bloodstream and digestive system isolates. J. Clin. Microbiol. 48:4028-4034.
14. Escribano P, Recio S, Peláez T, Bouza E, Guinea J. 2011. Aspergillus fumigatus strains with mutations in the cyp51A gene do not always show phenotypic resistance to itraconazole, voriconazole, or posaconazole. Antimicrob. Agents Chemother. 55:2460-2462.
15. Escribano P, et al. 2012. In vitro acquisition of secondary azole resistance in Aspergillus fumigatus isolates after prolonged exposure to itraconazole: presence of heteroresistant populations. Antimicrob. Agents Chemother. 56:174-178.
16. Feil EJ. 2004. Small change: keeping pace with microevolution. Nat. Rev. Microbiol. 2:483-495. (Pubitemid 39200015)
17. Herbrecht R, et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415. (Pubitemid 34851833)
18. Howard SJ, et al. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068-1076.
19. Howard SJ, Arendrup MC. 2011. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med. Mycol. 49(Suppl. 1):S90-S95.
20. Illnait-Zaragozi M-T, et al. 2010. Microsatellite typing of clinical and environmental Cryptococcus neoformans var. grubii isolates from Cuba shows multiple genetic lineages. PLoS One 5:e9124. doi:10.1371/journal.pone.0009124.
21. Leroux P, Albertini C, Gautier A, Gredt M, Walker A-S. 2007. Mutations in the Cyp51 gene correlated with changes in sensitivity to sterol 14 alpha-demethylation inhibitors in field isolates of Mycosphaerella graminicola. Pest Manag. Sci. 63:688-698. (Pubitemid 47025963)
22. Lockhart SR, et al. 2011. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob. Agents Chemother. 55:4465-4468.
23. Rudramurthy SM, de Valk HA, Chakrabarti A, Meis JFGM, Klaassen CHW. 2011. High resolution genotyping of clinical Aspergillus flavus isolates from India using microsatellites. PLoS One 6:e16086. doi:10.1371/journal.pone.0016086.
24. Saeed AI, et al. 2003. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34:374-378. (Pubitemid 36184095)
25. Snelders E, et al. 2012. Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS One 7:e31801. doi:10.1371/journal.pone.0031801.
26. Snelders E, et al. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5:e219. doi:10.1371/journal.pmed.0050219.
27. Ullmann AJ, et al. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356:335-347. (Pubitemid 46148776)
28. van der Linden JWM, et al. 2011. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg. Infect. Dis. 17:1846-1854.
29. Vanhee LME, Symoens F, Nelis HJ, Coenye T. 2008. Microsatellite typing of Aspergillus fumigatus isolates recovered from deep organ samples of patients with invasive aspergillosis. Diagn. Microbiol. Infect. Dis. 62:96-98.
30. Verweij PE, Howard SJ, Melchers WJG, Denning DW. 2009. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist. Updat. 12:141-147.